#South Korea #Seongnam #Clinical Trial #SN BioScience #SNB-101

Introduction

SN BioScience Inc., a promising biotechnology firm located in South Korea, has announced a significant milestone in the fight against Extensive-Stage Small Cell Lung Cancer (ES-SCLC). Today, the company revealed that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial for SNB-101, a nanoparticle anticancer agent that targets this aggressive form of lung cancer.

Trial Overview

This multi-center clinical trial is set to take place across various sites worldwide, including the United States and Europe, and aims to enroll a total of up to 135 patients. The trial comprises three sequential phases, starting with Phase 1b, which will utilize a 3+3 design to ascertain the Maximum Tolerated Dose (MTD) of SNB-101 at dosing levels between 50–70 mg/m². Following this, the study will transition into the second phase (Phase 2), which is further split into two parts: Phase 2a and 2b.

Phase 1b Insights

In the Phase 1 portion conducted in Korea, SNB-101 showcased premier results, exhibiting a favorable safety profile devoid of any Grade 3 or higher diarrhea events. It recorded an impressive disease control rate (DCR) of 83.3% within the higher dose cohorts and reported a mean progression-free survival (PFS) of 6.3 months among SCLC patients. These encouraging results have prompted comparisons with currently available late-line treatment options such as Zepzelca® and Topotecan, demonstrating SNB-101’s potential in providing an effective alternative.

Regulatory Milestones

Impressively, these Phase 1 findings led to SNB-101 receiving Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of SCLC, coupled with Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA). These designations signify that SNB-101 fulfills the necessary regulatory criteria for expedited approval, significantly boosting its development trajectory.

Further Development Plans

As a monotherapy, SNB-101 is showing potential for clinical activity while maintaining a favorable tolerability profile, especially among patients who have previously undergone treatment for SCLC. SN BioScience is optimistic about these outcomes and is keen on the continued clinical development of SNB-101 as a viable treatment option for relapsed SCLC, particularly in later-line treatment scenarios where both tolerability and efficacy are of paramount importance.

In parallel to the ongoing studies, SN BioScience is enthused about expanding SNB-101's development into combination therapies with several immunotherapy agents, namely those targeting PD-1, PD-L1, and DLL3 via BiTE® T-cell engager therapies, which are part of the standard treatment for SCLC. The company has already secured EMA approval to initiate a clinical study evaluating the efficacy of SNB-101 in conjunction with another immunotherapy agent. Moreover, there are plans for submitting additional Clinical Trial Applications (CTA) later this year for studies featuring other novel immunotherapy combinations.

Broader Horizons

Beyond SCLC, SN BioScience has set its sights on exploring additional solid tumor indications such as gastric and pancreatic cancers. Active collaborations and strategic discussions with global pharmaceutical entities are underway to broaden the scope of SNB-101's applicability and enhance its therapeutic potential.

Conclusion

With its innovative approach and commitment to addressing critical unmet medical needs in oncology, SN BioScience’s efforts in developing SNB-101 present a beacon of hope for patients battling Extensive-Stage Small Cell Lung Cancer. As this trial unfolds, all eyes will be on the outcomes that follow, marking a pivotal moment in advanced cancer treatment alternatives.